Physician profile
Olukemi Wallace
NPI 1609804350
$11,891.72
in general payments reported to CMS, 2019-2025
65 companies · $3,760 in 2025
The $3,760 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.23 · 2020: $28.86 · 2021: $103 · 2022: $75.50 · 2023: $3,510 · 2024: $4,319 · 2025: $3,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,782 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,782.06 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $528.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,135.85 | 2019-2025 | |
| Pfizer INC. | $1,042.04 | 2023-2025 | |
| Celgene Corporation | $645.48 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $498.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $471.85 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $455.14 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $404.58 | 2023-2025 | Iclusig, Alunbrig, Ninlaro |
| Astrazeneca Pharmaceuticals Lp | $382.42 | 2023-2025 | Enhertu, Tagrisso, Wainua |
| Daiichi Sankyo INC. | $373.51 | 2023-2025 | Enhertu, Vanflyta |
| Eisai INC. | $303.36 | 2023-2025 | |
| Janssen Biotech, INC. | $297.60 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Alexion Pharmaceuticals, INC. | $288.58 | 2023-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $283.55 | 2019-2023 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $279.97 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $269.50 | 2024-2025 | Braftovi, Mektovi, Tukysa |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $259.30 | 2023-2025 | Nerlynx |
| Genentech USA, INC. | $241.04 | 2021-2025 | Tecentriq, Phesgo |
| Astellas Pharma US INC | $217.99 | 2023-2025 | Vyloy, Xospata |
| Lilly USA, LLC | $201.67 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $172.48 | 2023-2025 | Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.09 | 2023-2025 | Gilotrif |
| Stemline Therapeutics INC. | $142.87 | 2023-2025 | Orserdu, Elzonris |
| Sun Pharmaceutical Industries INC. | $141.38 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $125.64 | 2023-2024 | Libtayo, Dupixent |
| Sobi, INC | $124.23 | 2023-2025 | |
| Pharmaessentia USA Corporation | $119.02 | 2023-2025 | Besremi |
| Beigene USA, INC. | $116.65 | 2023-2024 | Brukinsa |
| Genzyme Corporation | $114.54 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $110.97 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Exelixis INC. | $101.82 | 2023-2025 | Cabometyx |
| Blueprint Medicines Corporation | $95.29 | 2023-2024 | Ayvakit |
| Glaxosmithkline, LLC. | $93.27 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Aveo Pharmaceuticals, INC. | $90.98 | 2023-2025 | Fotivda |
| Emd Serono, INC. | $90.89 | 2023-2024 | Bavencio |
| Morphosys, US INC. | $63.83 | 2023-2024 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $63.72 | 2023-2024 | Provenge |
| Pharmacosmos Therapeutics INC. | $53.09 | 2023-2025 | Monoferric |
| Seagen INC. | $52.18 | 2023 | Padcev, Tukysa |
| Progenics Pharmaceuticals, INC. | $47.70 | 2023-2025 | Pylarify |
| Kyowa Kirin, INC. | $47.17 | 2024-2025 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $46.63 | 2023 | Imbruvica, Epkinly |
| Agios Pharmaceuticals, INC. | $45.86 | 2024-2025 | Pyrukynd |
| Recordati_rare_diseases_inc. | $44.55 | 2023-2025 | Sylvant |
| Jazz Pharmaceuticals INC. | $44.38 | 2021 | |
| Intuitive Surgical, INC. | $43.53 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $43.44 | 2023-2024 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $38.27 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $35.64 | 2023 | Xpovio |
| Genmab U.S., INC. | $33.80 | 2025 | Epkinly |
| Caris Mpi, INC. | $33.44 | 2025 | Mi Cancer Seek |
| Chiesi USA, INC. | $31.12 | 2023-2024 | Ferriprox |
| Syndax Pharmaceuticals, INC. | $28.65 | 2025 | |
| Legend Biotech USA INC. | $26.56 | 2025 | Carvykti |
| Verity Pharmaceuticals INC. | $24.83 | 2023 | Trelstar |
| Fennec Pharmaceuticals, INC. | $24.71 | 2023 | Pedmark |
| Octapharma USA, INC. | $21.30 | 2023 | Panzyga |
| Taiho Oncology, INC. | $20.53 | 2024 | |
| Cti Biopharma Corp. | $20.50 | 2023 | Vonjo |
| Kite Pharma, INC. | $20.34 | 2025 | Yescarta |
| Azurity Pharmaceuticals, INC. | $19.60 | 2025 | Danziten |
| Foundation Medicine, INC. | $18.97 | 2023 | Foundationone Liquid Cdx |
| Immunogen, INC. | $16.58 | 2023 | Elahere |
| Novocure INC. | $15.16 | 2025 | Optune Gio |
| Beone Medicines USA, INC. | $14.12 | 2025 | Brukinsa |
| Accord Healthcare, INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olukemi Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.